Equillium to Participate in Upcoming Investor Conferences
Equillium (Nasdaq: EQ) announced that management will participate in the Stifel 2026 Healthcare Conference on November 12, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Equillium (Nasdaq: EQ) announced that management will participate in the Stifel 2026 Healthcare Conference on November 12, 2026. The program includes a fireside chat at 9:20 AM EST and one-on-one meetings.
Management will also hold one-on-one meetings at the 2026 Jefferies Global Healthcare Conference in London on November 17–19, 2026. Meetings are available to investors registered for each conference.
Details
Market Reaction – EQ
On Nov 6, the first trading day after this news, the latest delayed price for EQ is 11.15% above the previous close. Our momentum scanner has recorded 12 alerts for this stock so far that day. The latest delayed price is $1.48.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
AI-generated analysis. How Rhea-AI works. Not financial advice.
LA JOLLA, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat serious autoimmune and inflammatory disorders, today announced that management will participate in the following upcoming investor conferences:
Stifel 2026 Healthcare Conference
Format: Fireside Chat & 1x1 Meetings
Date: Thursday, November 12, 2026
Time: 9:20 AM EST
2026 Jefferies Global Healthcare Conference in London
Format: 1x1 Meetings
Date: Tuesday, November 17 – Thursday, November 19, 2026
Members of the Equillium management team will be available to meet with investors who are registered to attend each conference.
About Equillium
Equillium is a biotechnology innovator with a mission to develop highly impactful therapies to treat serious autoimmune and inflammatory disorders.
For more information, visit www.equilliumbio.com.
Investor Contact
PJ Kelleher
LifeSci Advisors, LLC
+1-617-430-7579
pkelleher@lifesciadvisors.com
